SPRYHealthcare · BiotechnologyThe 4 Wall Street analysts covering ARS Pharmaceuticals, Inc. hold a median 12-month price target of $28 — +665.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 9 of 100 as at 28 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores ARS Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (57): Smaller than most of the companies we track.
Momentum (8): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on SPRY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +665.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Aug 2026 | Leerink Partners | Maintains | Outperform | $24 → $18 |
| 25 June 2026 | Leerink Partners | Maintains | Outperform | $25 → $24 |
| 25 June 2026 | Leerink Partners | Maintains | Outperform | — |
| 28 May 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 4 Sept 2025 | Roth Capital | Initiates | Buy | — |
| 7 Mar 2025 | Scotiabank | Initiates | Sector Outperform | — |
| 14 Jan 2025 | Raymond James | Maintains | Strong Buy | — |
| 13 Jan 2025 | Leerink Partners | Maintains | Outperform | — |
| 8 Oct 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 20 Sept 2024 | Leerink Partners | Maintains | Outperform | — |
| 16 Sept 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 9 Sept 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 20 Aug 2024 | Cantor Fitzgerald | Initiates | Overweight | — |
| 13 Aug 2024 | Raymond James | Upgrade | Strong Buy | — |
| 25 July 2024 | Raymond James | Initiates | Outperform | — |
| 11 Mar 2024 | Wedbush | Reiterates | Outperform | — |
| 5 Mar 2024 | Leerink Partners | Upgrade | Outperform | — |
| 13 Nov 2023 | Wedbush | Maintains | Outperform | — |
| 21 Sept 2023 | Wedbush | Maintains | Outperform | — |
| 20 Sept 2023 | William Blair | Downgrade | Market Perform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SPRY appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, ARS Pharmaceuticals, Inc. returned −59.2% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 4% of US stocks
Cheaper than 38% of US stocks
Cheaper than 3% of US stocks
Cheaper than 73% of US stocks
Higher than 93% of US stocks
Higher than 85% of US stocks
Higher than 75% of US stocks
Higher than 11% of US stocks
Higher than 3% of US stocks
Higher than 7% of US stocks
Higher than 8% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
ARS Pharmaceuticals, Inc. has a market value of $370.9M and an enterprise value of $398.7M.
Revenue in the twelve months to 30 June 2026: $116.9M. The latest quarter grew 114.2% year on year.
Net income over the same four quarters: −$215.4M, a −184.2% net margin.
Free cash flow in the twelve months to 30 June 2026: −$196.6M.
Trailing P/E: 168.3×; forward P/E: −4.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
ARS Pharmaceuticals, Inc. employs 195 people — $600K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| SPRYARS Pharmaceuticals, Inc. | $370.9M | 9 |
| CAPRCapricor Therapeutics, Inc. | $358.3M | 17 |
| GALTGalectin Therapeutics, Inc. | $357.0M | 69 |
| KYTXKyverna Therapeutics, Inc. | $356.0M | 36 |
| CTNMContineum Therapeutics, Inc. | $354.6M | 32 |
| RLMDRelmada Therapeutics, Inc. | $351.4M | 64 |
| FENCFennec Pharmaceuticals, Inc. | $371.1M | 90 |
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own ARS Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research says ARS Pharmaceuticals lacks the combination of factors it associates with a likely earnings beat ahead of the company’s upcoming report. The headline raises the possibility of negative earnings.
Why it matters — SPRY watchers may want to note the unfavorable earnings-beat outlook ahead of next week’s release.
ARS Pharmaceuticals announced it will host a conference call and webcast on November 5, 2026, to review its third-quarter 2026 financial results.
Why it matters — The event will provide SPRY watchers with the company’s third-quarter financial results and a related management update.
The DJS Law Group is reminding investors about a class action lawsuit filed against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. Shareholders who purchased SPRY shares during the stated class period are invited to contact the firm regarding possible lead plaintiff appointments.
Why it matters — A securities class action lawsuit against the company raises legal and regulatory concerns that SPRY shareholders and watchers would want to monitor.
Law firm SBS is reminding SPRY investors of a securities fraud class action lawsuit against ARS Pharmaceuticals, alleging violations of the Securities Exchange Act of 1934. The firm is encouraging shareholders who purchased during the class period to contact it regarding lead plaintiff appointments.
Why it matters — The announcement alerts SPRY watchers to pending securities fraud litigation against the company, which could carry legal and financial implications.
Rosen Law Firm reminds purchasers of ARS Pharmaceuticals securities who bought between March 9, 2026 and June 24, 2026 of the October 5, 2026 lead plaintiff deadline in a securities fraud lawsuit. Investors may be entitled to compensation through a contingency fee arrangement without out-of-pocket costs.
Why it matters — SPRY watchers should be aware of an active securities fraud lawsuit and the approaching lead plaintiff deadline for shareholders who purchased during the covered period.
The 4 Wall Street analysts covering ARS Pharmaceuticals, Inc. have a median 12-month price target of $28, with estimates ranging from $15 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering ARS Pharmaceuticals, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ARS Pharmaceuticals, Inc. 9 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, ARS Pharmaceuticals, Inc. ranks 9 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (57 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +665.0% from the last close, and Ticker Nerd's factor model ranks ARS Pharmaceuticals, Inc. 9 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering ARS Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SPRY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $30 over the next 12 months.
ARS Pharmaceuticals, Inc. returned -59.2% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Ars Pharmaceuticals Inc. specializes in the biopharmaceutical sector, focusing on the development of innovative, self-administered therapeutics aimed at improving patient outcomes.
The most recent item we track (Zacks Investment Research, 29 Oct 2026): "ARS Pharmaceuticals, Inc. (SPRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release". Zacks Investment Research says ARS Pharmaceuticals lacks the combination of factors it associates with a likely earnings beat ahead of the company’s upcoming report. The headline raises the possibility of negative earnings.
Ars Pharmaceuticals Inc. specializes in the biopharmaceutical sector, focusing on the development of innovative, self-administered therapeutics aimed at improving patient outcomes. The company's primary purpose is to advance medical solutions for allergy-related indications, enhancing safety and convenience for patients affected by conditions such as allergic reactions requiring rapid intervention. Notable for its emphasis on creating user-friendly delivery mechanisms, Ars Pharmaceuticals tailors its offerings to both patients and healthcare professionals seeking reliable and effective emergency treatments. By addressing critical needs within the healthcare industry, Ars Pharmaceuticals plays a significant role in expanding options in allergy treatment and management. Its contributions to the medical field underscore its ongoing commitment to transforming therapeutic landscapes and meeting pressing health challenges.
CEO Mr. Donn Casale · 195 employees · United States · https://ars-pharma.com
